Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Current Assets (2016 - 2025)

Immucell's Current Assets history spans 16 years, with the latest figure at $16.9 million for Q4 2025.

  • For Q4 2025, Current Assets rose 12.64% year-over-year to $16.9 million; the TTM value through Dec 2025 reached $16.9 million, up 12.64%, while the annual FY2025 figure was $16.9 million, 12.64% up from the prior year.
  • Current Assets reached $16.9 million in Q4 2025 per ICCC's latest filing, up from $16.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $18.3 million in Q1 2022 to a low of $10.8 million in Q2 2024.
  • Average Current Assets over 5 years is $14.5 million, with a median of $15.3 million recorded in 2021.
  • Peak YoY movement for Current Assets: soared 61.77% in 2021, then plummeted 36.83% in 2023.
  • A 5-year view of Current Assets shows it stood at $16.3 million in 2021, then fell by 13.96% to $14.0 million in 2022, then decreased by 18.04% to $11.5 million in 2023, then skyrocketed by 31.15% to $15.0 million in 2024, then increased by 12.64% to $16.9 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Current Assets are $16.9 million (Q4 2025), $16.8 million (Q3 2025), and $17.1 million (Q2 2025).